Skip to main content

Table 9 The risk of bias and study quality for each fibromyalgia review

From: A comparison of two assessment tools used in overviews of systematic reviews: ROBIS versus AMSTAR-2

Fibromyalgia

AMSTAR-2

ROBIS

Multiple CAM therapies

 Holdcraft 2003 [14]

CL

Low

 Baronowsky 2009 [15]

CL

High

 Terhorst 2011, 2012 [16, 17]

CL

High

 De Silva 2010 [18]

CL

High

Homoeopathy

 Perry 2010 [19]

CL

Low

 Boehm 2014 [20]

CL

High

Chiropractic treatment

 Ernst 2009 [21]

CL

Unclear

Acupuncture

 Mayhew and Ernst 2007 [22]

CL

Low

 Daya 2007 [23]

CL

Low

 Langhorst 2010 [24]

CL

Low

 Martin-Sanchez 2009 [25]

CL

High

 Cao 2013 [26]

CL

Low

 Deare 2013 [13]

LOW

Low

 Yang 2014 [27]

CL

High

Herbal medicines

 de Souza Nascimento 2013 [28]

CL

Low

  1. When AMSTAR-2 is low, this should correspond to ROBIS being of high risk of bias. The italicised reviews show discrepancies between the overall rating of quality/bias